2024-12-13 01:34:07
Latest Post
Premium Lingerie Brand MHYTH Raises Angel Funding, achieves Over $1M Valuation Within a month of launch
Sodhani Academy of Fintech Enablers Ltd enters into agreement with BFSI SSC
Ashok Leyland Ltd receives order for 1475 BSVI Diesel Passenger Bus Chassis from TNSTC
Operations of MDF plant at Greenply Speciality Panels Pvt Ltd suspended due to machinery breakdown
GHCL got Environment Clearance for Soda Ash Greenfield Plant
Stock Report
Emcure Pharmaceuticals Ltd Q2 FY2025 consolidated PAT soars to Rs. 194.57 crores
Posted On : 2024-11-07 23:39:59( TIMEZONE : IST )
Emcure Pharmaceuticals Limited has reported Consolidated financial results for the period ended September 30, 2024.
Financial Results (Q2 FY2025) - QoQ Comparison
The company has reported total income of Rs. 2037.638 crores during the period ended September 30, 2024 as compared to Rs. 1838.579 crores during the period ended June 30, 2024.
The company has posted net profit / (loss) of Rs. 194.572 crores for the period ended September 30, 2024 as against net profit / (loss) of Rs. 144.081 crores for the period ended June 30, 2024.
The company has reported EPS of Rs. 10.33 for the period ended September 30, 2024 as compared to Rs. 7.95 for the period ended June 30, 2024.
| Financials | Q2 FY2025 | Q1 FY2025 | % Change |
| Total Income | ₹2037.638 crs | ₹1838.579 crs |  10.83% |
| Net Profit | ₹194.572 crs | ₹144.081 crs | 35.04% |
| EPS | ₹10.33 | ₹7.95 | 29.94% |
Financial Results (Q2 FY2025) - YoY Comparison
The company has reported total income of Rs.2037.638 crores during the period ended September 30, 2024 as compared to Rs.1664.423 crores during the period ended September 30, 2023.
The company has posted net profit / (loss) of Rs.194.572 crores for the period ended September 30, 2024 as against net profit / (loss) of Rs.139.154 crores for the period ended September 30, 2023.
The company has reported EPS of Rs.10.33 for the period ended September 30, 2024 as compared to Rs.7.70 for the period ended September 30, 2023.
| Financials | Q2 FY2025 | Q2 FY2024 | % Change |
| Total Income | ₹2037.638 crs | ₹1664.423 crs | 22.42% |
| Net Profit | ₹194.572 crs | ₹139.154 crs | 39.82% |
| EPS | ₹10.33 | ₹7.70 | 34.16% |
Financial Results (Half Year Ended FY2025) - YoY Comparison
The company has reported total income of Rs.3876.217 crores during the 6 Months period ended September 30, 2024 as compared to Rs.3235.563 crores during the 6 Months period ended September 30, 2023.
The company has posted net profit / (loss) of Rs.338.653 crores for the 6 Months period ended September 30, 2024 as against net profit / (loss) of Rs.269.562 crores for the 6 Months period ended September 30, 2023.
The company has reported EPS of Rs.18.33 for the 6 Months period ended September 30, 2024 as compared to Rs.14.91 for the 6 Months period ended September 30, 2023.
| Financials | Half Year Ended FY2025 | Half Year Ended FY2024 | % Change |
| Total Income | ₹3876.217 crs | ₹3235.563 crs | 19.80% |
| Net Profit | ₹338.653 crs | ₹269.562 crs | 25.63% |
| EPS | ₹18.33 | ₹14.91 | 22.94% |
Shares of Emcure Pharmaceuticals Limited was last trading in BSE at Rs. 1437.35 as compared to the previous close of Rs. 1444.25. The total number of shares traded during the day was 2776 in over 471 trades.
The stock hit an intraday high of Rs. 1456.00 and intraday low of 1425.00. The net turnover during the day was Rs. 3999517.00.
